scispace - formally typeset
T

Tsui-Fen Chou

Researcher at California Institute of Technology

Publications -  93
Citations -  7468

Tsui-Fen Chou is an academic researcher from California Institute of Technology. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 23, co-authored 67 publications receiving 6618 citations. Previous affiliations of Tsui-Fen Chou include University of California, Los Angeles & UCLA Medical Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways

Tsui-Fen Chou, +13 more
- 22 Mar 2011 - 
TL;DR: N2,N4-Dibenzylquinazoline-2,4-diamine (DBeQ) was identified as a selective, potent, reversible, and ATP-competitive p97 inhibitor that blocks multiple processes that have been shown by RNAi to depend on p97, including degradation of ubiquitin fusion degradation and endoplasmic reticulum-associated degradation pathway reporters.
Journal ArticleDOI

Chemically Controlled Self-Assembly of Protein Nanorings

Jonathan C. T. Carlson, +5 more
- 17 May 2006 - 
TL;DR: It is demonstrated that, in the presence of dimeric methotrexate, wild-type Escherichia coli dihydrofolate reductase molecules tethered together by a flexible peptide linker are capable of spontaneously forming highly stable cyclic structures with diameters ranging from 8 to 20 nm.
Journal ArticleDOI

Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPase

Tsui-Fen Chou, +5 more
- 01 Feb 2013 - 
TL;DR: The results nominate ML240 as a promising starting point for the development of a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway‐specific p97 inhibitors.
Journal ArticleDOI

A novel mutation in VCP causes Charcot–Marie–Tooth Type 2 disease

Michael A. Gonzalez, +11 more
- 01 Nov 2014 - 
TL;DR: Functional studies showed that the Glu185Lys variant impaired autophagic function leading to the accumulation of immature autophagosomes, and should be considered for genetically undefined Charcot-Marie-Tooth disease type 2.